To include your compound in the COVID-19 Resource Center, submit it here.

Chiron's FGF-2 misses end point

CHIR said that in a double-blind, placebo-controlled Phase II trial of its FGF-2 to treat peripheral artery disease

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE